Unibest

Pharmaceutical intermediates

Niraparib Intermediates

2 pharmaceutical intermediates for Niraparib. Indication: Ovarian Cancer; Peritoneal Cancer; Epithelial Ovarian Cancer; Fallopian Tube Cancer.

提交项目All intermediates

About Niraparib

Originator
Tesaro Inc; MSD
Indication
Ovarian Cancer; Peritoneal Cancer; Epithelial Ovarian Cancer; Fallopian Tube Cancer
Approved Date
03/27/2017
DS/DP
08/12/2027

Available intermediates

2 intermediates currently listed for Niraparib. Request specifications, documentation or a quotation for any item below.

Niraparib intermediates
Product NameCAS No.Molecular FormulaPhysical Properties
Methyl 3-formyl-2-nitrobenzoate138229-59-1//
(S)-tert-butyl 3-(4-aMinophenyl)piperidine-1-carboxylate1171197-20-8//

Other programs under N

Nafamostat mesylateNebivolol HydrochlorideNemorexantNeratinib/ PyrotinibNilotinibNintedanib Esylate

Building toward Niraparib?

Tell us the step you need covered and the specification you are filing against. We will confirm supply, documentation and lead time.

提交项目 联系团队

我们能如何帮助您？

获取最新活动与法规动态洞察

直接发送到您的邮箱

在此获取行业洞察与 Unibest 动态

联系我们 →